title: Lymphocyte subset reconstitution after allogeneic bone marrow transplantation using radiation-free conditioning regimen for patients with chronic granulocytic leukemia.
abstract: Conditioning regimens for BMT are important in determining transplant outcome. A radiation-free protocol containing Mitobronitol (DBM), Cytarabine (Ara-C) and Cyclophosphamide (Cy) was used for conditioning of patients with chronic granulocytic leukemia (CGL). Using this conditioning treatment, fewer transplant related complications, including acute GVHD, VOD and severe infections, were observed. Acute GVHD did not develop, but chronic GVHD, accompanied with graft-versus leukemia, was present in half of the cases. To determine the clinical effect of the DBM/Ara-C/Cy conditioning, the recovery of peripheral blood lymphocytes was examined after allogeneic BMT for patients with CGL in comparison with TBI/Cy conditioning. The lymphocyte subsets of 11 DBM patients were followed and analyzed periodically (30-90 days, 4-12 months and > 13 months) using ten monoclonal antibodies and flow cytometry. Decreased percentage of total T cells as well as CD4+ and CD8+ subpopulations, significantly decreased T cell activation and increased proportion of TCR gamma delta + cells were found to be characteristic in the early post-transplant period in the DBM group. Early recovery and consistently higher percentage of B cells were observed for the whole follow-up period of patients receiving DBM conditioning. A high proportion of NK cells was observed in all transplant recipients. These findings suggest that the characteristic pattern of recovering lymphocytes is associated with the lack of severe transplant-related clinical complications following DBM/Ara-C/Cy conditioning.
authors.affiliation: National Institute of Haematology, Blood Transfusion and Immunology, Semmelweis University Medical School, Budapest, Hungary.
authors.forename: J
authors.initials: J
authors.lastname: Milosevits
authors.forename: R
authors.initials: R
authors.lastname: Dénes
authors.forename: A
authors.initials: A
authors.lastname: Poros
authors.forename: P
authors.initials: P
authors.lastname: Reményi
authors.forename: A
authors.initials: A
authors.lastname: Bátai
authors.forename: A
authors.initials: A
authors.lastname: Barta
authors.forename: T
authors.initials: T
authors.lastname: Masszi
authors.forename: L
authors.initials: L
authors.lastname: Lengyel
authors.forename: K
authors.initials: K
authors.lastname: Jakab
authors.forename: J
authors.initials: J
authors.lastname: Földi
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000502:physiology*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D016131:Lymphocyte Subsets; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents